Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.26 and traded as low as $0.22. Northwest Biotherapeutics shares last traded at $0.22, with a volume of 3,307,507 shares changing hands.
Northwest Biotherapeutics Stock Performance
The stock has a market capitalization of $325.27 million, a price-to-earnings ratio of -3.19 and a beta of -1.12. The company's 50 day moving average is $0.27 and its 200 day moving average is $0.26.
Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) last released its earnings results on Thursday, May 15th. The biotechnology company reported ($0.01) EPS for the quarter. The company had revenue of $0.38 million for the quarter.
Northwest Biotherapeutics Company Profile
(
Get Free Report)
Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Northwest Biotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Northwest Biotherapeutics wasn't on the list.
While Northwest Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
